Please login to the form below

Not currently logged in
Email:
Password:

warfarin

This page shows the latest warfarin news and features for those working in and with pharma, biotech and healthcare.

Xarelto no better than aspirin in secondary stroke study

Xarelto no better than aspirin in secondary stroke study

The overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin, but Xarelto has seen

Latest news

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin.

  • Bayer defends Xarelto as pivotal trial scrutinised Bayer defends Xarelto as pivotal trial scrutinised

    The trial used a device called INRatio, manufactured by Alere, to determine whether doses of warfarin should be adjusted to keep the drug in the right therapeutic range. ... The implication is that patients on warfarin may have been more prone to bleeds

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    Meanwhile, anticoagulants such as warfarin and the newer novel oral anticoagulant (NOAC) class can prevent clots from forming but are unable to dissolve them when already present.

  • NICE recommends Daiichi Sankyo's Lixiana for DVT and PE NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

    around £26, 000 per quality-adjusted life year (QALY), though it noted there are no definitive costs for warfarin monitoring. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better bleeding profile

  • Daiichi’s new anticoagulant recommended by NICE Daiichi’s new anticoagulant recommended by NICE

    warfarin that patients and physicians appreciate.”. ... The first OAC, which was approved more than 50 years ago, is the generic warfarin, but in recent years a spate of new drugs has come onto the market for AF

More from news
Approximately 2 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Bringing about digital health change Bringing about digital health change

    Roche believes it is on to a winner with its CoaguChek system, developed in collaboration with QL, to help warfarin patients self monitor so they don't have to travel to

  • Pharma–payer partnerships – rhetoric or reality? Pharma–payer partnerships – rhetoric or reality?

    The class is likely to replace the current standard of care (warfarin) which has been around for over 50 years. ... Despite being considered a 'dirty' drug warfarin has spawned the development of complex blood monitoring clinics and associated medical

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics